ArticleMolecular biology reports2026
Altered expression of KCNQ1OT1 and ZEB1-AS1 lncRNAs in autism spectrum disorder: A case-control study.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAutism spectrum disorder (ASD) is a complex neurodevelopmental condition with a significant genetic basis, although its multifactorial etiology remains poorly understood. Emerging evidence suggests that long non-coding RNAs (lncRNAs) play critical roles in gene regulation and in modulating key signaling pathways, including extracellular matrix (ECM), which are crucial for neural development.
methodsIn this study, we examined the expression levels of three lncRNAs; TGFβ2-AS1, KCNQ1OT1, and ZEB1-AS1; in peripheral blood samples collected from 30 individuals with ASD and 41 age and gender matched healthy controls. Total RNA was extracted, and gene expression was quantified using real-time quantitative PCR.
resultsThe results revealed a significant upregulation of ZEB1-AS1 (approximately 20-fold increase, p < 0.0001) and a striking downregulation of KCNQ1OT1 (nearly 30-fold decrease, p < 0.0001) in ASD patients. In contrast, TGFβ2-AS1 expression showed no significant change. A positive correlation was also observed between KCNQ1OT1 expression and patient age. Receiver operating characteristic (ROC) curve analyses demonstrated strong diagnostic potential for KCNQ1OT1 and ZEB1-AS1, with AUC values of 0.91 and 0.88, respectively.
conclusionsOverall, these findings suggest that dysregulation of specific lncRNAs may contribute to ASD pathogenesis and highlight KCNQ1OT1 and ZEB1-AS1 as promising diagnostic biomarkers and potential therapeutic targets.
Indexed as
Identifiers
42268498What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.